4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

L Macía-Rivas; CL Fernández-Laguna; FJ Álvarez-Manceñido; A Arias-Martínez; A Martínez-Torrón; I Macías-Declara; JM Cano-Cano; M Diez; A Custodio; J López-Robles; A Lozano-Blázquez

doi:10.1136/ejhpharm-2023-eahp.203

Article info

Section 4: Clinical pharmacy services

4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

Free

Authors

L Macía-Rivas Universidad de Santiago de Compostela / Hospital Universitario Central de Asturias, Doctoral Programme In Medicine Clinical Research / Hospital Pharmacy, Santiago de Compostela, Spain PubMed articles Google scholar articles
CL Fernández-Laguna Hospital Universitario Central de Asturias, Hospital Pharmacy, Oviedo, Spain PubMed articles Google scholar articles
FJ Álvarez-Manceñido Hospital Universitario Central de Asturias, Hospital Pharmacy, Oviedo, Spain PubMed articles Google scholar articles
A Arias-Martínez University of Granada / Hospital Universitario Germans Trias I Pujol, Doctoral Programme In Pharmacy- Faculty of Pharmacy / Pharmacy Department, Granada, Spain PubMed articles Google scholar articles
A Martínez-Torrón University of Granada / Hospital Universitario Central de Asturias, Doctoral Programme In Pharmacy- Faculty of Pharmacy / Hospital Pharmacy, Granada, Spain PubMed articles Google scholar articles
I Macías-Declara Hospital Universitario Parc Tauli, Medical Oncology, Sabadell, Spain PubMed articles Google scholar articles
JM Cano-Cano Hospital General Universitario de Ciudad Real, Medical Oncology, Ciudad Real, Spain PubMed articles Google scholar articles
M Diez Hospital Universitario Vall D’hebron, Medical Oncology, Barcelona, Spain PubMed articles Google scholar articles
A Custodio Hospital Universitario la Paz, Medical Oncology Department / Ciberonc Cb16/12/00398, Madrid, Spain PubMed articles Google scholar articles
J López-Robles Hospital Universitario Morales Meseguer, Medical Oncology, Murcia, Spain PubMed articles Google scholar articles
A Lozano-Blázquez Hospital Universitario Central de Asturias, Hospital Pharmacy, Oviedo, Spain PubMed articles Google scholar articles

Citation

Macía-Rivas L, Fernández-Laguna C, Álvarez-Manceñido F, et al

4CPS-219 Agamenon-seom model for the prediction of survival in patients with HER2-positive advanced oesophagogastric adenocarcinoma receiving trastuzumab-based first-line treatment

European Journal of Hospital Pharmacy 2023;30:A96-A97.

Publication history

First published March 23, 2023.

Online issue publication

May 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password